Cantor Fitzgerald reiterated Overweight for Zai Lab stock at USD 37.00

Published on 10/13/2026 at 06:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Product revenue rose 11.00 percent to USD 105.80 million in the second quarter. An October 23 call and October 26 poster frame Zai Lab stock.

Key points in brief

Cantor Fitzgerald reiterated an Overweight rating and a USD 37.00 price target on October 6, 2026.
Zai Lab reported USD 105.80 million in net product revenue for the second quarter of 2026, up 11.00 percent sequentially.
The company plans an investor call on October 23, 2026, ahead of first global zocilurtatug data at an October 26, 2026, ESMO poster.
Zai Lab's market capitalization was USD 2.8 billion as of October 12, 2026.

ZLAB, US98887Q1040, Illustration mit AI erstellt.

Cantor Fitzgerald reiterated an Overweight rating and a USD 37.00 price target for Zai Lab on October 6, 2026, according to Investing.com. Global Banking and Finance identifies Zai Lab Limited as the Nasdaq-listed issuer with ticker ZLAB and ISIN US98887Q1040.

Three milestones shape the story

On August 6, 2026, Zai Lab reported second-quarter results, including USD 105.80 million in net product revenue and 11.00 percent sequential growth, according to Benzinga.

On September 29, 2026, Zai Lab announced that global clinical data for zocilurtatug pelitecan would be presented at the ESMO Congress, with the poster scheduled for October 26, 2026, according to Zai Lab.

On October 6, 2026, Cantor Fitzgerald kept its Overweight rating and USD 37.00 target, while the reported analyst target range stood at USD 24.25 to USD 50.00, according to Investing.com.

What ESMO means for the pipeline

The October data point matters because Zai Lab is testing zocilurtatug in combination with atezolizumab, with or without carboplatin, in first-line extensive-stage small cell lung cancer. Management said the dataset is expected to cover about 60 patients, with median follow-up of 8 to 9 months, according to Benzinga.

The commercial base also gives the pipeline room to develop. In the second quarter of 2026, net product revenue reached USD 105.80 million, while the business remained commercially profitable; cash stood at USD 717.50 million at quarter-end, according to Benzinga.

Reported adjusted earnings per share for the second quarter was a USD 0.05 loss, compared with a consensus USD 0.60 loss, while quarterly revenue reached USD 106.30 million versus USD 104.34 million expected, according to Investing.com. That comparison places the October 23 investor call and October 26 poster at the center of the next evidence cycle.

Upcoming dates carry the catalyst

Zai Lab scheduled an investor conference call for October 23, 2026, at 8:00 a.m. ET to discuss the ESMO data and zocilurtatug development plans, according to Zai Lab. The ESMO poster is scheduled for October 26, 2026, at 12:00 p.m. CEST.

The company is therefore approaching a defined clinical readout rather than a general pipeline update. For investors, the key comparison is whether the first-line combination data can improve on the 60.00 percent to 70.00 percent response benchmark and five-month median progression-free survival cited in the earnings call.

Zai Lab enters the data window

Zai Lab had a market capitalization of USD 2.8 billion as of October 12, 2026. The October 6 analyst view leaves the stock with a USD 37.00 target against a reported USD 25.62 reference price in the analyst note, while the company enters October with a quantified clinical timetable and second-quarter product revenue of USD 105.80 million.